Your browser doesn't support javascript.
loading
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua, Melvin L K; Lo, Winnie; Pintilie, Melania; Murgic, Jure; Lalonde, Emilie; Bhandari, Vinayak; Mahamud, Osman; Gopalan, Anuradha; Kweldam, Charlotte F; van Leenders, Geert J L H; Verhoef, Esther I; Hoogland, Agnes Marije; Livingstone, Julie; Berlin, Alejandro; Dal Pra, Alan; Meng, Alice; Zhang, Junyan; Orain, Michèle; Picard, Valérie; Hovington, Hélène; Bergeron, Alain; Lacombe, Louis; Fradet, Yves; Têtu, Bernard; Reuter, Victor E; Fleshner, Neil; Fraser, Michael; Boutros, Paul C; van der Kwast, Theodorus H; Bristow, Robert G.
Affiliation
  • Chua MLK; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Lo W; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Pintilie M; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Murgic J; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Lalonde E; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Bhandari V; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Mahamud O; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Gopalan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kweldam CF; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van Leenders GJLH; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Verhoef EI; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Hoogland AM; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Livingstone J; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Berlin A; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Dal Pra A; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Meng A; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Zhang J; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Orain M; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Picard V; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Hovington H; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Bergeron A; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Lacombe L; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Fradet Y; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Têtu B; Centre de Recherche du CHU de Québec-Université Laval, Québec City, QC, Canada.
  • Reuter VE; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fleshner N; Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Fraser M; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.
  • Boutros PC; Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
  • van der Kwast TH; Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands; Laboratory Medicine Program, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: Theodorus.vanderKwast@uhn.ca.
  • Bristow RG; Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address: Rob.Bristow@rmp.uhn.on.ca.
Eur Urol ; 72(5): 665-674, 2017 11.
Article in En | MEDLINE | ID: mdl-28511883
BACKGROUND: Intraductal carcinoma (IDC) and cribriform architecture (CA) represent unfavorable subpathologies in localized prostate cancer. We recently showed that IDC shares a clonal ancestry with the adjacent glandular adenocarcinoma. OBJECTIVE: We investigated for the co-occurrence of "aggression" factors, genomic instability and hypoxia, and performed gene expression profiling of these tumors. DESIGN, SETTING, AND PARTICIPANTS: A total of 1325 men were treated for localized prostate cancer from four academic institutions (University Health Network, CHU de Québec-Université Laval, Memorial Sloan Kettering Cancer Center [MSKCC], and Erasmus Medical Center). Pathological specimens were centrally reviewed. Gene copy number and expression, and intraprostatic oxygenation were assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: IDC/CA was separately assessed for biochemical relapse risk in the Canadian and MSKCC cohorts. Both cohorts were pooled for analyses on metastasis. RESULTS AND LIMITATION: Presence of IDC/CA independently predicted for increased risks of biochemical relapse (HRCanadian 2.17, p<0.001; HRMSKCC 2.32, p=0.0035) and metastasis (HRpooled 3.31, p<0.001). IDC/CA+ cancers were associated with an increased percentage of genome alteration (PGA [median] 7.2 vs 3.0, p<0.001), and hypoxia (64.0% vs 45.5%, p=0.17). Combinatorial genomic-pathological indices offered the strongest discrimination for metastasis (C-index 0.805 [clinical+IDC/CA+PGA] vs 0.786 [clinical+IDC/CA] vs 0.761 [clinical]). Profiling of mRNA abundance revealed that long noncoding RNA, SChLAP1, was the only gene expressed at >3-fold higher (p<0.0001) in IDC/CA+ than in IDC/CA- tumors, independently corroborated by increased SChLAP1 RNA in situ hybridization signal. Optimal treatment intensification for IDC/CA+ prostate cancer requires prospective testing. CONCLUSIONS: The poor outcome associated with IDC and CA subpathologies is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia. We posit a novel concept in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality. PATIENT SUMMARY: A constellation of unfavorable molecular characteristics co-occur with intraductal and cribriform subpathologies in prostate cancer. Modern imaging for surveillance and treatment intensification trials should be considered in this adverse subgroup.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma / Biomarkers, Tumor / Genomic Instability / RNA, Long Noncoding Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Country/Region as subject: America do norte / Europa Language: En Journal: Eur Urol Year: 2017 Document type: Article Affiliation country: Canadá Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Adenocarcinoma / Biomarkers, Tumor / Genomic Instability / RNA, Long Noncoding Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Country/Region as subject: America do norte / Europa Language: En Journal: Eur Urol Year: 2017 Document type: Article Affiliation country: Canadá Country of publication: Suiza